Martin Südmeyer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Martin Südmeyer has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Alfons Schnitzler
Institute of Clinical Neuroscience and Medical Psychology, Medical Faculty, Heinrich Heine University Düsseldorf, Germany
9 shared publications - Lars Wojtecki
Department for Neurology and Neurorehabilitation, Hospital Zum Heiligen Geist, Academic Teaching Hospital of the Heinrich-Heine-University Duesseldorf, 47906 Kempen, Germany
7 shared publications - Jens Volkmann
Department of Neurology, University Hospital Würzburg, Würzburg, Germany
2 shared publications L. Wojtecki
Neurologische Klinik, Zentrum für Bewegungsstörungen und Neuromodulation, Medizinische Fakultät, UKD, Düsseldorf, Düsseldorf, Deutschland
2 shared publicationsLars Dinkelbach
Department of Neurology Medical Faculty University Düsseldorf Düsseldorf Germany; Institute of Clinical Neuroscience and Medical Psychology Heinrich Heine University Düsseldorf Germany
2 shared publicationsSaskia Elben
Department of Neurology and Institute of Clinical Neuroscience and Medical Psychology, Heinrich Heine University, Duesseldorf, Germany
2 shared publications
Latest Publications
- Open Access
- 19 September 2015
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 2 (11) , 1029-1031
Cervical dystonia caused by focal putaminal ischemia
- 19 September 2015
- Published by Wiley in Annals of Clinical and Translational Neurology
- Vol. 2 (11) , 1029-1031
Open AccessCervical dystonia caused by focal putaminal ischemia
- Open Access
- 18 August 2015
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 6, 177
A Prospective Pilot Trial for Pallidal Deep Brain Stimulation in Huntington’s Disease
Background: Movement disorders in Huntington´s disease are often medically refractive. The aim of the trial was assessment of procedure safety of deep brain stimulation, equality of internal- and external-pallidal stimulation and efficacy followed-up for 6 months in a prospective pilot trial. Methods: In a conrolled double-blind phase 6 patients (4 chorea-dominant, 2 Westphal-variant) with predominant movement disorder were randomly assigned to either the sequence of 6 week internal-/6 week external-pallidal stimulation, or vice versa, followed by further 3 months chronic pallidal stimulation at the target with best effect-side-effect ratio. Primary endpoints were changes in the Unified Huntington´s Disease Rating Scale motor-score, chorea subscore and total motor-score 4 (blinded video ratings), comparing internal- versus external-pallidal stimulation, and 6 month versus baseline. Secondary endpoints assessed scores on dystonia, hypokinesia, cognition, mood, functionality/disability and quality-of-life. Results: Intention-to-treat analysis of all patients (n=3 in each treatment sequence): Both targets were equal in terms of efficacy. Chorea subscores decreased significantly over 6 months (-5.3 (60.2%), p=0.037). Effects on dystonia were not significant over the group due to it consisting of three responders (>50% improvement) and three non-responders. Westphal patients did not improve. Cognition was stable. Mood and some functionality/disability and quality-of-life scores improved significantly. 8 adverse events and 2 additional serious adverse events - mostly internal-pallidal stimulation-related - resolved without sequalae. No procedure-related complications occurred. Conclusion: Pallidal deep brain stimulation was demonstrated to be a safe treatment option for the reduction of chorea in Huntington´s disease. Their effects on chorea and dystonia and on quality-of-life, should be examined in larger controlled trials.
- 18 August 2015
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 6, 177
Open AccessA Prospective Pilot Trial for Pallidal Deep Brain Stimulation in Huntington’s Disease
Background: Movement disorders in Huntington´s disease are often medically refractive. The aim of the trial was assessment of procedure safety of deep brain stimulation, equality of internal- and external-pallidal stimulation and efficacy followed-up for 6 months in a prospective pilot trial. Methods: In a conrolled double-blind phase 6 patients (4 chorea-dominant, 2 Westphal-variant) with predominant movement disorder were randomly assigned to either the sequence of 6 week internal-/6 week external-pallidal stimulation, or vice versa, followed by further 3 months chronic pallidal stimulation at the target with best effect-side-effect ratio. Primary endpoints were changes in the Unified Huntington´s Disease Rating Scale motor-score, chorea subscore and total motor-score 4 (blinded video ratings), comparing internal- versus external-pallidal stimulation, and 6 month versus baseline. Secondary endpoints assessed scores on dystonia, hypokinesia, cognition, mood, functionality/disability and quality-of-life. Results: Intention-to-treat analysis of all patients (n=3 in each treatment sequence): Both targets were equal in terms of efficacy. Chorea subscores decreased significantly over 6 months (-5.3 (60.2%), p=0.037). Effects on dystonia were not significant over the group due to it consisting of three responders (>50% improvement) and three non-responders. Westphal patients did not improve. Cognition was stable. Mood and some functionality/disability and quality-of-life scores improved significantly. 8 adverse events and 2 additional serious adverse events - mostly internal-pallidal stimulation-related - resolved without sequalae. No procedure-related complications occurred. Conclusion: Pallidal deep brain stimulation was demonstrated to be a safe treatment option for the reduction of chorea in Huntington´s disease. Their effects on chorea and dystonia and on quality-of-life, should be examined in larger controlled trials.
- 1 August 2015
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 21 (8) , 976-980
Cognitive outcome of pallidal deep brain stimulation for primary cervical dystonia: One year follow up results of a prospective multicenter trial
- 1 August 2015
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 21 (8) , 976-980
Cognitive outcome of pallidal deep brain stimulation for primary cervical dystonia: One year follow up results of a prospective multicenter trial
- Open Access
- 1 January 2014
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 4, 218
Effect of Subthalamic Stimulation on Voice and Speech in Parkinson’s Disease: For the Better or Worse?
Background: Deep brain stimulation of the subthalamic nucleus, although highly effective for the treatment of motor impairment in Parkinson´s disease, can induce speech deterioration in a subgroup of patients. The aim of the current study was to survey 1) if there are distinctive stimulation effects on the different parameters of voice and speech and 2) if there is a special pattern of preexisting speech abnormalities indicating a risk for further worsening under stimulation. Methods: N = 38 patients with Parkinson´s disease had to perform a speech test without medication with stimulation ON and OFF. Speech samples were analysed: 1) according to a four-dimensional perceptual speech score and 2) by acoustic analysis to obtain quantifiable measures of distinctive speech parameters.Results: Quality of voice was ameliorated with stimulation ON, and there were trends to increased loudness and better pitch variability. N = 8 patients featured a deterioration of speech with stimulation ON, caused by worsening of articulation or/and fluency. These patients had more severe overall speech impairment with characteristic features of articulatory slurring and articulatory acceleration already under StimOFF condition.Conclusion: The influence of subthalamic stimulation on Parkinsonian speech differs considerably between individual patients, however, there is a trend to amelioration of voice quality and prosody. Patients with stimulation-associated speech deterioration featured higher overall speech impairment and showed a distinctive pattern of articulatory abnormalities at baseline. Further investigations to confirm these preliminary findings are necessary to allow neurologists to pre-surgically estimate the individual risk of deterioration of speech under stimulation.
- 1 January 2014
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 4, 218
Open AccessEffect of Subthalamic Stimulation on Voice and Speech in Parkinson’s Disease: For the Better or Worse?
Background: Deep brain stimulation of the subthalamic nucleus, although highly effective for the treatment of motor impairment in Parkinson´s disease, can induce speech deterioration in a subgroup of patients. The aim of the current study was to survey 1) if there are distinctive stimulation effects on the different parameters of voice and speech and 2) if there is a special pattern of preexisting speech abnormalities indicating a risk for further worsening under stimulation. Methods: N = 38 patients with Parkinson´s disease had to perform a speech test without medication with stimulation ON and OFF. Speech samples were analysed: 1) according to a four-dimensional perceptual speech score and 2) by acoustic analysis to obtain quantifiable measures of distinctive speech parameters.Results: Quality of voice was ameliorated with stimulation ON, and there were trends to increased loudness and better pitch variability. N = 8 patients featured a deterioration of speech with stimulation ON, caused by worsening of articulation or/and fluency. These patients had more severe overall speech impairment with characteristic features of articulatory slurring and articulatory acceleration already under StimOFF condition.Conclusion: The influence of subthalamic stimulation on Parkinsonian speech differs considerably between individual patients, however, there is a trend to amelioration of voice quality and prosody. Patients with stimulation-associated speech deterioration featured higher overall speech impairment and showed a distinctive pattern of articulatory abnormalities at baseline. Further investigations to confirm these preliminary findings are necessary to allow neurologists to pre-surgically estimate the individual risk of deterioration of speech under stimulation.
- 1 September 2012
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 18 (8) , 1002
Multiple subcutaneous abscesses and necroses due to apomorphine pump treatment
- 1 September 2012
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 18 (8) , 1002
Multiple subcutaneous abscesses and necroses due to apomorphine pump treatment
- Open Access
- 27 July 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (7) , e41873
Longitudinal Deformation-Based Morphometry Reveals Spatio-Temporal Dynamics of Brain Volume Changes in Patients with Corticobasal Syndrome
Corticobasal syndrome (CBS) is a rare neurodegenerative disorder characterized by a progressive and asymmetric manifestation of cortical and basal-ganglia symptoms of different origin. The spatio-temporal dynamics of cerebral atrophy in CBS is barely known. This study aimed to longitudinally quantify the individual dynamics of brain volume changes in patients with CBS as compared to healthy controls. We used deformation-field-based morphometry (DFM) to study volumetric changes of each individual brain in short intervals of a few months. DFM enabled the quantitative analysis of local volume changes without predefining regions of interest in MR images of 6 patients with CBS and 11 matched healthy controls. A total of 64 whole brain 3D-MR-scans were acquired two to eight times over periods of 14 to 26 months. Based on repeated registrations of MR observations to the initial scan, maps of local volume ratio changes were computed. Compared to controls patients showed significant and increasing volume loss over time in premotor and primary-motor-cortices, somatosensory area 3a, superior parietal areas BA 5/7, and corticospinal tract. Furthermore, significant and asymmetric atrophy was identified in the caudate nucleus head, putamen, pallidum, motor-thalamus and substantia nigra. Temporal lobe was affected in those patients who presented progressive cognitive impairment. The analysis revealed localized, pathological changes in brains of patients with CBS, which differed significantly from those occurring during aging in healthy controls. As compared to age- and sex-matched controls, brains of CBS patients showed a common degenerating neural network comprising the motor circuit with basal ganglia and motor thalamic nuclei as well as the premotor and primary-motor-cortex.
- 27 July 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (7) , e41873
Open AccessLongitudinal Deformation-Based Morphometry Reveals Spatio-Temporal Dynamics of Brain Volume Changes in Patients with Corticobasal Syndrome
Corticobasal syndrome (CBS) is a rare neurodegenerative disorder characterized by a progressive and asymmetric manifestation of cortical and basal-ganglia symptoms of different origin. The spatio-temporal dynamics of cerebral atrophy in CBS is barely known. This study aimed to longitudinally quantify the individual dynamics of brain volume changes in patients with CBS as compared to healthy controls. We used deformation-field-based morphometry (DFM) to study volumetric changes of each individual brain in short intervals of a few months. DFM enabled the quantitative analysis of local volume changes without predefining regions of interest in MR images of 6 patients with CBS and 11 matched healthy controls. A total of 64 whole brain 3D-MR-scans were acquired two to eight times over periods of 14 to 26 months. Based on repeated registrations of MR observations to the initial scan, maps of local volume ratio changes were computed. Compared to controls patients showed significant and increasing volume loss over time in premotor and primary-motor-cortices, somatosensory area 3a, superior parietal areas BA 5/7, and corticospinal tract. Furthermore, significant and asymmetric atrophy was identified in the caudate nucleus head, putamen, pallidum, motor-thalamus and substantia nigra. Temporal lobe was affected in those patients who presented progressive cognitive impairment. The analysis revealed localized, pathological changes in brains of patients with CBS, which differed significantly from those occurring during aging in healthy controls. As compared to age- and sex-matched controls, brains of CBS patients showed a common degenerating neural network comprising the motor circuit with basal ganglia and motor thalamic nuclei as well as the premotor and primary-motor-cortex.
- 8 June 2012
- Published by Springer Nature in Der Diabetologe
- Vol. 8 (4) , 275-279
Teleneurologie beim M. Parkinson
- 8 June 2012
- Published by Springer Nature in Der Diabetologe
- Vol. 8 (4) , 275-279
Teleneurologie beim M. Parkinson
- 13 November 2011
- Published by Springer Nature in Der Nervenarzt
- Vol. 83 (4) , 481-486
Tiefe Hirnstimulation – Erwartungen und Bedenken
- 13 November 2011
- Published by Springer Nature in Der Nervenarzt
- Vol. 83 (4) , 481-486
Tiefe Hirnstimulation – Erwartungen und Bedenken
- Open Access
- 15 April 2011
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 52 (5) , 733-740
Diagnostic Accuracy of Combined FP-CIT, IBZM, and MIBG Scintigraphy in the Differential Diagnosis of Degenerative Parkinsonism: A Multidimensional Statistical Approach
In vivo molecular imaging of pre- and postsynaptic nigrostriatal neuronal degeneration and sympathetic cardiac innervation with SPECT is used to distinguish idiopathic Parkinson disease (PD) from atypical parkinsonian disorder (APD). However, the diagnostic accuracy of these imaging approaches as stand-alone procedures is often unsatisfying. The aim of this study was therefore to evaluate to which extent diagnostic accuracy can be increased by their combined use together with a multidimensional statistical algorithm. Methods: The SPECT radiotracers 123I-(S)-2-hydroxy-3-iodo-6-methoxy-N-[1-ethyl-2-pyrrodinyl)-methyl]benzamide (IBZM), 123I-N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropan (FP-CIT), and meta-123I-iodobenzylguanidine (MIBG) were used to assess striatal postsynaptic D2 receptor binding, striatal presynaptic dopamine transporter binding, and myocardial adrenergic innervation, respectively. Thirty-one PD and 17 APD patients were prospectively investigated. PD and APD diagnoses were established using consensus criteria and reevaluated after 37.4 ± 12.4 and 26 ± 11.6 mo in PD and APD, respectively. Test accuracy (TA) for PD–APD differentiation was computed for all logical (Boolean) combinations of imaging modalities by receiver-operating-characteristic analysis—that is, after multidimensional optimization of cutoff values. Results: Analysis showed moderate TA for PD–APD differentiation using each molecular approach alone (IBZM, 79%; MIBG, 73%; and FP-CIT, 73%). For combined use, the highest TA resulted under the assumption that at least 2 of the 3 biologic markers had to be positive for APD using the following cutoff values: 1.46 or less for IBZM, less than 2.10 for FP-CIT, and greater than 1.43 for MIBG. This algorithm distinguished APD from PD with a sensitivity of 94%, specificity of 94% (TA, 94%), positive predictive value of 89%, and negative predictive value of 97%. Conclusion: Results suggest that the multidimensional combination of FP-CIT, IBZM, and MIBG scintigraphy is likely to significantly increase TA in differentiating PD from APD. The differential diagnosis of degenerative parkinsonism may thus be facilitated.
- 15 April 2011
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 52 (5) , 733-740
Open AccessDiagnostic Accuracy of Combined FP-CIT, IBZM, and MIBG Scintigraphy in the Differential Diagnosis of Degenerative Parkinsonism: A Multidimensional Statistical Approach
In vivo molecular imaging of pre- and postsynaptic nigrostriatal neuronal degeneration and sympathetic cardiac innervation with SPECT is used to distinguish idiopathic Parkinson disease (PD) from atypical parkinsonian disorder (APD). However, the diagnostic accuracy of these imaging approaches as stand-alone procedures is often unsatisfying. The aim of this study was therefore to evaluate to which extent diagnostic accuracy can be increased by their combined use together with a multidimensional statistical algorithm. Methods: The SPECT radiotracers 123I-(S)-2-hydroxy-3-iodo-6-methoxy-N-[1-ethyl-2-pyrrodinyl)-methyl]benzamide (IBZM), 123I-N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropan (FP-CIT), and meta-123I-iodobenzylguanidine (MIBG) were used to assess striatal postsynaptic D2 receptor binding, striatal presynaptic dopamine transporter binding, and myocardial adrenergic innervation, respectively. Thirty-one PD and 17 APD patients were prospectively investigated. PD and APD diagnoses were established using consensus criteria and reevaluated after 37.4 ± 12.4 and 26 ± 11.6 mo in PD and APD, respectively. Test accuracy (TA) for PD–APD differentiation was computed for all logical (Boolean) combinations of imaging modalities by receiver-operating-characteristic analysis—that is, after multidimensional optimization of cutoff values. Results: Analysis showed moderate TA for PD–APD differentiation using each molecular approach alone (IBZM, 79%; MIBG, 73%; and FP-CIT, 73%). For combined use, the highest TA resulted under the assumption that at least 2 of the 3 biologic markers had to be positive for APD using the following cutoff values: 1.46 or less for IBZM, less than 2.10 for FP-CIT, and greater than 1.43 for MIBG. This algorithm distinguished APD from PD with a sensitivity of 94%, specificity of 94% (TA, 94%), positive predictive value of 89%, and negative predictive value of 97%. Conclusion: Results suggest that the multidimensional combination of FP-CIT, IBZM, and MIBG scintigraphy is likely to significantly increase TA in differentiating PD from APD. The differential diagnosis of degenerative parkinsonism may thus be facilitated.
- 29 July 2010
- Published by Springer Nature in Journal of Neurology
- Vol. 258 (1) , 140-142
Action tremor caused by olivary cavernoma in Klippel–Trénaunay syndrome mimicking asymmetric essential tremor
- 29 July 2010
- Published by Springer Nature in Journal of Neurology
- Vol. 258 (1) , 140-142
Action tremor caused by olivary cavernoma in Klippel–Trénaunay syndrome mimicking asymmetric essential tremor